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Water Docket 
U.S. Environmental Protection Agency 
Mailcode 2822T 
1200 Pennsylvania Avenue, NW 
Washington, D.C. 20460 
   
 
Docket ID No. EPA-HQ-OW-2008-0692. Drinking Water: Preliminary Regulatory 
Determination on Perchlorate 
 
The Massachusetts Department of Environmental Protection (MassDEP) is submitting the 
following comments in response to the United States Environmental Protection Agency’s 
(EPA’s) request for comment on its preliminary determination not to regulate perchlorate in 
drinking water at a national level, Docket ID No. EPA–HQ– OW–2008–0692 entitled “Drinking 
Water:  Preliminary Regulatory Determination on Perchlorate”.   These comments were prepared 
by scientists in the MassDEP Office of Research and Standards (ORS) including Carol Rowan 
West, MPH, Director, ORS; Tsedash Zewdie Ph.D., Senior Toxicologist, ORS; and C. Mark 
Smith Ph.D., S.M., Deputy Director, ORS.  
 
1.  A Health Protective National Standard is Needed. MassDEP disagrees with EPA’s draft 
decision not to regulate perchlorate at the national level and believes that a health protective 
national drinking water standard for perchlorate is both warranted and necessary to protect the 
health of our nation’s children. Overall, EPA’s assessment does not adequately support its 
determination to not regulate perchlorate for a sizeable number of United State’ citizens, by 
disregarding elevated exposures and potential developmental effects in the neonate. This 
decision is inconsistent with basic precepts of public health protection.  
 
2.  EPA’s HRL Is Not Sufficiently Health Protective. MassDEP continues to believe that 
EPA’s Reference Dose (RfD) and the associated Health Reference Level (HRL) for drinking 
water  for perchlorate are insufficiently health protective of neonatal exposures. There is 
compelling evidence to support a national drinking water standard for perchlorate at a value well 
below EPA’s HRL of 15 ppb.  
  
• Literature publications (Zoeller and Rice, 2004; Zoeller, 2006; Ginsberg et al., 2007) and 
state agency risk assessments (MassDEP, 2006; CA, 2004) support a more health 
protective RfD and drinking water value. EPA’s HRL of 15 ppb is 7.5 times higher than 
MassDEP’s drinking water standard of 2 ppb and 2.5 times higher than California’s 
standard of 6 ppb.  EPA’s evaluation includes no discussion of these alternative 
assessments. 
• The results of Blount et al (2006) and Steinmaus et al (2007) demonstrate thyroid effects 
associated with a dose of 0.06 ug/kg/day in iodide insufficient women, which is well 
below, and calls into question the protectiveness of, EPA’s RfD of 0.7 ug/kg/day.  
• Although acknowledged in EPA’s evaluation, potential interactive effects between 
thiocyanate, a metabolite of cyanide found in tobacco smoke and some common foods, 
and perchlorate, were not accounted for. Such interactions heighten concern regarding 
perchlorate induced thyroid hormone effects in women with serum iodine levels < 100 
ug/L.  
• Use of a more appropriate and health protective RfD would lower the acceptable drinking 
water limit for perchlorate, resulting in a substantial increase in the total number of 
citizens exposed to unacceptably high levels of this toxicant from drinking water. This 
would clearly create a "meaningful opportunity for health risk reduction" through a 
national perchlorate drinking water regulation under the Safe Water Drinking Act. 
 
3. Infant Exposures at the HRL Exceed EPA’s Insufficiently Protective RfD. EPA’s 
calculations (Table 8, Federal Register publication) demonstrate that perchlorate intake by 
nursing and bottle-fed infants and children to 2 years of age, attributable to the consumption of 
drinking water at 15 ug/L (and not even considering other dietary sources of exposure) would 
substantially exceed EPA’s insufficiently health protective RfD value. Based on EPA’s own 
calculations, a bottle-fed infant would receive a dose of perchlorate 5 times higher than EPA’s 
RfD and 50 times higher than MassDEP’s RfD.  Consistent with EPA’s assessment, in a study 
conducted in Texas Dasgupta et al. (2008) also showed that the majority the infants (9 out 13 
infants) in their study ingested perchlorate at a level that exceeds the EPA reference dose. 
Furthermore, this study indicates that breast milk iodide concentrations decrease as perchlorate 
levels increase in breast milk (Dasgupta et al., 2008), potentially raising risks to nursing infants. 
Due to potential impacts on children’s health, this data alone justifies the establishment of a 
lower, more appropriately health protective HRL for perchlorate. By discounting this 
information in the evaluation, EPA is de facto adopting an even higher, less protective RfD for 
these sensitive subgroups.  EPA’s explanation for discounting these findings- that the model’s 
predicted iodide uptake inhibition (IUI) level at 15 ppb would be insignificant- is unjustified for 
at least three reasons.  
a. The predicted IUI in these groups is very uncertain due to model limitations. 
b. Although EPA indicates that iodide uptake inhibition of 2.2% is non-adverse, no 
objective data exists to support this determination and no objective safe level of IUI, 
especially in the neonate, has been established.   In fact, the Blount et al. (2006) and 
Steinamus et al. (2007) studies indicate that 2.6 ug/L of urinary perchlorate (which 
equates to an approximate dose level of 0.06 ug/kg/d in iodine deficient women was 
associated with decreased T4 and increased TSH levels, consistent with the mode of 
action of perchlorate. Iodide uptake inhibition at this dose level would be predicted by the 
model to be very small suggesting either that the model is inaccurate; the effect is not 
solely due to IUI or low levels of IUI are adverse.  
c. Allowing up to 2.2% iodine uptake inhibition also exceeds NRC’s hypothesized non-
adverse effect level of 1.8% IUI (NRC, 2005) although 1.8% IUI is considered an 
adverse effect level by many scientists (US EPA 2002; Ginsberg and Rice, 2005; and 
MassDEP, 2006).   
 
4.  The PBPK Model is Uncertain Especially for Iodine Insufficient Women. Instead of using 
the standard approach of comparing estimated doses to the RfD to determine safe drinking water 
levels, EPA is instead relying on physiologically-based pharmacokinetic (PBPK) modeling to 
predict IUI.  MassDEP believes that the PBPK modeling has a number of limitations and may be 
less reliable.  For example, the PBPK modeling does not adequately address effects in iodide 
insufficient populations and is very uncertain with respect to predicted breast milk perchlorate 
concentrations, effects on neonates and impacts during early fetal development. Empirical data 
on these issues is sparse, limiting model construction and evaluation. More robust uncertainty 
analysis and evaluation of model outputs is needed.    
 
5. EPA Needs to Better Assess and Present PBPK Model Uncertainties.  Since EPA relies 
heavily on the outputs of the PBPK model to predict breast milk perchlorate levels, a more 
thorough presentation of the model, model uncertainties and its outputs, in particular for breast 
milk perchlorate concentrations and neonatal exposures under differing maternal exposure 
scenarios is needed. This information should be provided to the public for review and comment, 
in addition to a scientific peer review session.  These are uncertain because the PBPK model 
relied on rat data for several key parameters that influence breast milk perchlorate 
concentrations. Furthermore, the model was only evaluated against limited human data derived 
from populations in Chile (Tellez et al., 2005).  
 
6. US Data Indicates the PBPK Model May Underestimate Breast Milk Perchlorate. Due to 
differences in dietary iodide intake rates, which are likely to be much higher in Chile, as well as 
other factors, breast milk data from US populations with lower levels of iodine intake, such as 
from the Boston study (Pearce et al., 2007), should also be used for model evaluation. Based on 
the Pearce et al., study, MassDEP is concerned that the model may significantly underestimate 
perchlorate breast milk concentrations in US women. Table 1, compiled by MassDEP, compares 
observed perchlorate and iodide concentrations in breast milk and perchlorate in urine from the 
Chilean and Boston study populations. These data are consistent with higher dietary iodide 
intake levels in the Chilean populations compared to the Boston area. The US data also exhibits a 
higher breast milk to urine perchlorate concentration ratio compared to those observed in the 
Chilean study groups - a factor of 4 for the Boston data vs. a range of only 0.33 to 2 for the 
Chilean populations.  This suggests that the Boston women, perhaps due to lower iodide intake, 
may have partitioned a greater fraction of perchlorate dose into breast milk than predicted by the 
model. This would result in even higher neonatal exposures than predicted by EPA at a maternal 
drinking water concentration of 15 ug/L, which as noted above, already exceeds the RfD.  
 
Table 1. Lactational Perchlorate and Iodide levels in Urine and Breast Milk  
Sample type  N Antofagasta 
 
(CLO4- H2O 
conc. <4 µg/L) 
N Chanaral 
 
(CLO4- 
H2O conc. 
5.8 µg/L) 
N Talatal 
 
(CLO4- H2O 
conc. 114 
µg/L) 
 
N Boston  
 
CLO4- source 
unknown 
 
                                                                               Tellez et al. 2005         Pearce et al.,  2007 
Urine CLO4- (µg/L) 
(mean) 
6 22.3 ± 23.8 4 17.5 ± 10 16 49.1± 35.2 
 
56 8.2±19 
Breast milk CLO4- 
(µ g/L) (mean) 
13 
 
7.7 ± 7.5 16 18.3±17.7 25 95.6±54.6 49 33±77 
Breast milk iodine (µ 
g/L) (mean)* 
14 454 ±374 16 325 ± 150 25 384 ± 154 57 205 ± 271 
CLO4- Breast milk/to 
CLO4-urine Ratio 
 0.35  1.04  2.0  4.0 
* Note: The Pearce et al., paper states that the Boston population breast milk iodine concentrations were higher than 
in the Chilean populations. This is an apparent error as the concentration units were not adjusted to account for the 
fact that the Boston results were presented in units of ug/L vs. ug/dL in the Chilean populations.   
 
 
7. The PBPK Model is Deficient for Early Developmental Periods. Emerging data now 
indicate that thyroid hormone deficiency during early gestation causes neuronal toxicity (Sinah et 
al., 2008). The EPA has acknowledged that the lack of biological information during early fetal 
development limits the applicability of the PBPK modeling of the fetus and thus can not make 
meaningful predictions regarding early fetal IUI. 
 
8. The PBPK Model Does Not Consider Other Potential Mechanisms of Toxicity. 
Additionally, the model only addresses iodide uptake inhibition. However, perchlorate not only 
inhibits iodide uptake but also promotes the discharge of endogenous iodide, which is not 
addressed in EPA’s assessment. The thyroid gland possesses two kinds of iodide. The first is the 
iodide which is accumulated into the thyroid by an active transport mechanism, the so-called 
"transported iodide". The second source is the iodothyronins which are derived by hydrolysis 
from thyroglobulin and rapidly deiodinated within the gland to yield the so-called “endogenous 
iodide". It is believed that both iodide sources are used within the thyroid gland for the synthesis 
of hormones. Rosenberg et al., 1961; Isaacs et al., 1966; Greer et al., 1969 showed that 
perchlorate discharged endogenous iodide in animals, and Burgi et al.(1974) confirmed this 
phenomenon to occur in humans.   Wolff (1974) has attempted to propose mechanisms by which 
perchlorate accomplishes the discharge of stored thyroidal iodide, but how this process affects 
thyrocytes upon short- and long-term exposure is not well understood and is not covered by the 
PKPB modeling. 
 
9. MassDEP Believes That a National Perchlorate Drinking Water Standard Provides a 
Significant Risk Reduction Opportunity. Table 2 of the Federal Register publication provides 
information on the occurrence and population estimates for perchlorate above various thresholds.  
The table shows that up to 2.0 million people would be provided drinking water above 15 ppb, a 
value that, based on EPA’s own estimates, is not protective of the breast or bottle fed infant, yet 
which is EPA’s proposed HRL.  EPA does not explain in the Federal Register how it reached its 
conclusion that protecting up to 2.0 million people is not a meaningful opportunity for risk 
reduction for persons, in particular infants, served by public water systems. 
 
10.  EPA Underestimates Numbers of At Risk Citizens. Due to the fact that MassDEP 
believes the HRL should be 2 ppb we conclude more than 16.6 million people are exposed to 
unsafe levels of perchlorate in their drinking water, and that this is a significant national public 
health issue.    
 
In conclusion, EPA’s determination that a national drinking water is not warranted is based on an 
incomplete assessment of the data and will place many of the nation’s most vulnerable citizens, 
our newborn children and fetuses at an early stage of development, at risk.  MassDEP believes 
that there is compelling evidence to support a national drinking water standard for perchlorate at 
a value well below EPA’s HRL of 15 ppb.  
 
For further information please contact Carol Rowan West at 617-292-5510 
(Carol.RowanWest@state.ma.us) or C. Mark Smith at 617-292-5509 
(C.Mark.Smith@state.ma.us). 
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